REVLIMID Capsules Ref.[7409] Active ingredients: Lenalidomide

Source: European Medicines Agency (EU)  Revision Year: 2019  Publisher: Celgene Europe B.V., Winthontlaan 6 N, 3526 KV Utrecht, Netherlands

Product name and form

Revlimid 2.5 mg hard capsules.
Revlimid 5 mg hard capsules.
Revlimid 7.5 mg hard capsules.
Revlimid 10 mg hard capsules.
Revlimid 15 mg hard capsules.
Revlimid 20 mg hard capsules.
Revlimid 25 mg hard capsules.

Pharmaceutical Form

Hard capsule.

Revlimid 2.5 mg hard capsules: Blue-green/white capsules, size 4, 14.3 mm, marked “REV 2.5 mg”.

Revlimid 5 mg hard capsules: White capsules, size 2, 18.0 mm, marked “REV 5 mg”.

Revlimid 7.5 mg hard capsules: Pale yellow/white capsules, size 2, 18.0 mm, marked “REV 7.5 mg”.

Revlimid 10 mg hard capsules: Blue-green/pale yellow capsules, size 0, 21.7 mm, marked “REV 10 mg”.

Revlimid 15 mg hard capsules: Pale blue/white capsules, size 0, 21.7 mm, marked “REV 15 mg”.

Revlimid 20 mg hard capsules: Blue-green/pale blue capsules, size 0, 21.7 mm, marked “REV 20 mg”.

Revlimid 25 mg hard capsules: White capsules, size 0, 21.7 mm, marked “REV 25 mg”.

Qualitative and quantitative composition

Revlimid 2.5 mg hard capsules: Each capsule contains 2.5 mg of lenalidomide.

Excipient(s) with known effect: Each capsule contains 73.5 mg of lactose (as anhydrous lactose).

Revlimid 5 mg hard capsules: Each capsule contains 5 mg of lenalidomide.

Excipient(s) with known effect: Each capsule contains 147 mg of lactose (as anhydrous lactose).

Revlimid 7.5 mg hard capsules: Each capsule contains 7.5 mg of lenalidomide.

Excipient(s) with known effect: Each capsule contains 144.5 mg of lactose (as anhydrous lactose).

Revlimid 10 mg hard capsules: Each capsule contains 10 mg of lenalidomide.

Excipient(s) with known effect: Each capsule contains 294 mg of lactose (as anhydrous lactose).

Revlimid 15 mg hard capsules: Each capsule contains 15 mg of lenalidomide.

Excipient(s) with known effect: Each capsule contains 289 mg of lactose (as anhydrous lactose).

Revlimid 20 mg hard capsules: Each capsule contains 20 mg of lenalidomide.

Excipient(s) with known effect: Each capsule contains 244.5 mg of lactose (as anhydrous lactose).

Revlimid 25 mg hard capsules: Each capsule contains 25 mg of lenalidomide.

Excipient(s) with known effect: Each capsule contains 200 mg of lactose (as anhydrous lactose).

For the full list of excipients, see section 6.1.

Active Ingredient Description
Lenalidomide

The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties.

List of Excipients

Capsule contents:

Anhydrous lactose
Microcrystalline cellulose
Croscarmellose sodium
Magnesium stearate

Capsule shell:

Revlimid 2.5 mg/ 10 mg/ 20 mg hard capsules:

Gelatin
Titanium dioxide (E171)
Indigo carmine (E132)
Yellow iron oxide (E172)

Revlimid 5 mg/ 25 mg hard capsules:

Gelatin
Titanium dioxide (E171)

Revlimid 7.5 mg hard capsules:

Gelatin
Titanium dioxide (E171)
Yellow iron oxide (E172)

Revlimid 15 mg hard capsules:

Gelatin
Titanium dioxide (E171)
Indigo carmine (E132)

Printing ink:

Shellac
Propylene glycol
Black iron oxide (E172)
Potassium hydroxide

Pack sizes and marketing

Polyvinylchloride (PVC) / Polychlorotrifluoroethylene (PCTFE) / Aluminium foil blisters containing 7 hard capsules.

Revlimid 2.5 mg/5 mg/7.5 mg/10 mg/15 mg/20 mg/25 mg hard capsules: Pack size of 7 or 21 capsules. Not all pack sizes may be available.

Marketing authorization holder

Celgene Europe B.V., Winthontlaan 6 N, 3526 KV Utrecht, Netherlands

Marketing authorization dates and numbers

Revlimid 2.5 mg hard capsules:

EU/1/07/391/005

EU/1/07/391/007

Revlimid 5 mg hard capsules:

EU/1/07/391/001

EU/1/07/391/008

Revlimid 7.5 mg hard capsules:

EU/1/07/391/006

EU/1/07/391/012

Revlimid 10 mg hard capsules:

EU/1/07/391/002

EU/1/07/391/010

Revlimid 15 mg hard capsules:

EU/1/07/391/003

EU/1/07/391/011

Revlimid 20 mg hard capsules:

EU/1/07/391/009

EU/1/07/391/013

Revlimid 25 mg hard capsules:

EU/1/07/391/004

EU/1/07/391/014

Date of first authorisation: 14 June 2007

Date of latest renewal: 16 February 2017

Drugs

Drug Countries
REVLIMID Austria, Australia, Brazil, Canada, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Ireland, Israel, Japan, Lithuania, Mexico, Netherlands, New Zealand, Poland, Singapore, Tunisia, Turkey, United Kingdom, United States, South Africa

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.